Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma

NCT03057795 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

62

Enrollment

OTHER

Sponsor class

Conditions

Classic Hodgkin Lymphoma
Recurrent Hodgkin Lymphoma
Refractory Hodgkin Lymphoma

Interventions

DRUG: Brentuximab Vedotin
OTHER: Laboratory Biomarker Analysis
BIOLOGICAL: Nivolumab

Sponsor

City of Hope Medical Center

Collaborators

[object Object]